Table 3 Treatment Settings
Number of chemotherapy lines in recurrent or metastatic setting | Among the whole cohort (N = 198) | Among patients eligible for inclusion in a clinical trial (N = 131) |
|---|---|---|
No. of patients (%) | No. of patients (%) | |
1 | 74 (37) | 33 (25) |
2 | 47 (24) | 37 (28) |
3 | 44 (22) | 33 (25) |
4 | 23 (12) | 19 (15) |
5 or more | 10 (5) | 9 (7) |
Chemotherapy drug used | ||
Taxanes | 177 (89) | 122 (93) |
Including recurrent or metastatic setting | 162 (82) | 116 (89) |
CDDP or Carboplatin | 185 (93) | 127 (97) |
Including recurrent or metastatic setting | 154 (78) | 114 (87) |
5FU | 78 (39) | 62 (47) |
Including recurrent or metastatic setting | 36 (18) | 32 (24) |
Cetuximab | 144 (73) | 103 (79) |
Including recurrent or metastatic setting | 134 (68) | 100 (76) |
Capecitabine in recurrent or metastatic setting | 27 (14) | 23 (18) |
Methotrexate in recurrent or metastatic setting | 67 (34) | 39 (30) |
Novel agent tested in a clinical trial in recurrent or metastatic setting | 27 (14) | 27 (21) |
Drug combination used in first line of the recurrent/metastatic disease | ||
Platinum based combination | 143 (72) | 103 (79) |
Cisplatin + taxanes | 46 (23) | 40 (31) |
Carboplatin + taxanes | 69 (35) | 40 (31) |
Platinum without taxanes | 28 (14) | 23 (18) |
Including CDDP 5FU and cetuximab combination | 11 (6) | 10 (8) |
Taxanes and cetuximab combination | 14 (7) | 8 (6) |
Monotherapy | 34 (17) | 13 (10) |
Clinical trials testing not approved regimens | 7 (4) | 7 (5) |